Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNB NASDAQ:EWTX NASDAQ:IVA NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$9.23+1.4%$9.90$4.16▼$11.84$1.35B1.281.54 million shs1.71 million shsEWTXEdgewise Therapeutics$14.15+1.6%$13.91$10.60▼$38.12$1.47B0.26631,764 shs574,623 shsIVAInventiva$4.36+3.3%$3.35$1.53▼$4.36$403.70M0.7326,083 shs63,365 shsWVEWAVE Life Sciences$9.76+9.5%$7.67$5.04▼$16.74$1.42B-0.951.62 million shs2.88 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO+1.43%+0.76%-13.17%+18.64%+20.73%EWTXEdgewise Therapeutics+1.58%+11.59%+3.74%-4.26%-17.01%IVAInventiva+3.32%+21.79%+31.33%+40.19%+100.00%WVEWAVE Life Sciences+9.54%+20.64%+24.81%+54.19%+75.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89BIO1.9493 of 5 stars3.51.00.00.02.40.80.6EWTXEdgewise Therapeutics2.2787 of 5 stars3.52.00.00.02.32.50.0IVAInventiva3.6197 of 5 stars3.45.00.00.04.11.70.6WVEWAVE Life Sciences4.7555 of 5 stars4.51.00.04.83.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89BIO 3.00Buy$26.29184.79% UpsideEWTXEdgewise Therapeutics 2.90Moderate Buy$41.60193.99% UpsideIVAInventiva 2.80Moderate Buy$10.40138.53% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.27107.65% UpsideCurrent Analyst Ratings BreakdownLatest IVA, ETNB, EWTX, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/8/2025ETNB89BIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.008/8/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$48.00 ➝ $49.008/4/2025WVEWAVE Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.007/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/30/2025EWTXEdgewise TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$46.007/29/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$24.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/12/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/30/2025EWTXEdgewise TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89BION/AN/AN/AN/A$3.52 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$5.59 per shareN/AIVAInventiva$9.95M41.92N/AN/A($1.21) per share-3.60WVEWAVE Life Sciences$93.95M16.53N/AN/A$0.88 per share11.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%N/AEWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%N/AIVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%N/ALatest IVA, ETNB, EWTX, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89BION/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89BIO0.0715.1918.03EWTXEdgewise TherapeuticsN/A28.8720.99IVAInventivaN/A0.920.92WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89BION/AEWTXEdgewise TherapeuticsN/AIVAInventiva19.06%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipETNB89BIO2.60%EWTXEdgewise Therapeutics23.20%IVAInventiva32.00%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89BIO40148.31 million144.45 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableIVA, ETNB, EWTX, and WVE HeadlinesRecent News About These CompaniesWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells $85,192.70 in StockAugust 15 at 8:44 PM | marketbeat.comWave Life Sciences moved to not rated at JPMorganAugust 15 at 4:53 PM | msn.comInsider Selling: WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells 9,670 Shares of StockAugust 14 at 8:15 AM | insidertrades.comWave Life Sciences Shareholders Approve Key ProposalsAugust 11, 2025 | msn.comWave Life Sciences Earnings Call: Clinical Advances Amid Financial ChallengesAugust 9, 2025 | theglobeandmail.comKen Takanashi Sells 4,872 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) StockAugust 8, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ken Takanashi Sells 4,872 SharesAugust 8, 2025 | insidertrades.comWAVE Life Sciences (NASDAQ:WVE) Earns Buy Rating from Analysts at Canaccord Genuity GroupAugust 6, 2025 | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Now Covered by Canaccord Genuity GroupAugust 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Holdings Trimmed by TD Asset Management IncAugust 5, 2025 | marketbeat.comWave Life Sciences is a new Buy at Canaccord Genuity on near-term catalystsAugust 5, 2025 | msn.comCanaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationAugust 5, 2025 | msn.comB. Riley Reduces Earnings Estimates for WAVE Life SciencesAugust 4, 2025 | marketbeat.comFY2025 Earnings Forecast for WVE Issued By Cantor FitzgeraldAugust 4, 2025 | marketbeat.comResearch Analysts Issue Forecasts for WVE FY2025 EarningsAugust 4, 2025 | marketbeat.comQ3 EPS Forecast for WAVE Life Sciences Reduced by AnalystAugust 4, 2025 | marketbeat.comQ3 EPS Estimates for WAVE Life Sciences Decreased by WedbushAugust 4, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 6.3% Higher - Here's WhyAugust 2, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPSAugust 2, 2025 | marketbeat.comNeed To Know: The Consensus Just Cut Its Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates For 2025August 2, 2025 | finance.yahoo.comWAVE Life Sciences (NASDAQ:WVE) Price Target Lowered to $21.00 at Wells Fargo & CompanyAugust 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?By Nathan Reiff | July 22, 2025Post-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?By Nathan Reiff | August 11, 2025Full Steam Ahead: The Bullish Case for Carnival StockBy Jeffrey Neal Johnson | July 18, 2025IVA, ETNB, EWTX, and WVE Company Descriptions89BIO NASDAQ:ETNB$9.23 +0.13 (+1.43%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$9.50 +0.27 (+2.93%) As of 08/15/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Edgewise Therapeutics NASDAQ:EWTX$14.15 +0.22 (+1.58%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$14.15 0.00 (0.00%) As of 08/15/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Inventiva NASDAQ:IVA$4.36 +0.14 (+3.32%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$4.32 -0.04 (-0.83%) As of 08/15/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.WAVE Life Sciences NASDAQ:WVE$9.76 +0.85 (+9.54%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$9.88 +0.12 (+1.22%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore The Real Reason Ford Stock Is Rallying—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access